CINCINNATI, Jan. 19 /PRNewswire-FirstCall/ -- Kendle , a leading global full-service clinical research organization (CRO), today announced the appointment of Gregg Dearhammer to the newly created position of Vice President, Biometrics. In this role, Dearhammer will lead Kendle’s new global Biometrics operating unit, which provides Clinical Data Management, Biostatistics and Scientific Programming services on a stand-alone basis and as part of full-service Phase II-IV clinical development contracts for customers worldwide, including seven of the world’s 10 largest biopharmaceutical organizations. Previously, Kendle’s Biometrics services were organized under its Americas and Europe operating units, which focus on Phase I-III Clinical Development services, and the company’s Late Phase unit, which specializes in Phase IIIB/IV studies.
(Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO)
“Biometrics has long been a core competency for Kendle and is an area of tremendous outsourcing opportunity going forward,” said Christopher C. Bergen, President and Chief Operating Officer. “This move creates enhanced efficiencies for our customers through a streamlined Biometrics organization focused on delivery of high-quality global data solutions on time and on budget to expedite the clinical development process.” He continued, “We look forward to Gregg’s leadership as we build Kendle’s share of the growing market for Biometrics services.”
In his new role, Dearhammer will provide global leadership for Kendle’s Biometrics business, which includes data centers in the United States, Europe, Australia and Mexico staffed by nearly 500 associates. He will serve on the company’s Management Committee and will report directly to Chris Bergen.
Dearhammer joined Kendle in 1996 as Data Manager and has held positions of increasing responsibility, including Assistant Director and Director of the company’s North American Biometrics service offerings. He served most recently as Project Group Leader responsible for Biometrics services in North and Latin America. Dearhammer’s background also includes data management experience in the pharmaceutical industry. He holds a bachelor of science in biology from Loyola University in Chicago and is currently completing a master of science in business administration at Northern Kentucky University.
About Kendle
Kendle International Inc. is among the world’s leading global clinical research organizations. We deliver innovative and robust clinical development solutions -- from first-in-human studies through market launch and surveillance -- to help the world’s biopharmaceutical companies maximize product life cycles and grow market share. With the expertise of our nearly 2,000 associates worldwide, Kendle has conducted clinical trials or provided regulatory, pharmacovigilance and validation services in 70 countries. Additional information and investor kits are available upon request from Kendle, 1200 Carew Tower, 441 Vine Street, Cincinnati, OH 45202 or from the company’s Web site at http://www.kendle.com.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comKendle International Inc.
CONTACT: Investors, Patty Frank, +1-513-763-1992, or Media, Lori Dorer,+1-513-345-1685, both of Kendle International Inc.
Web site: http://www.kendle.com/